OptimizeRx (OPRX) Projected to Post Quarterly Earnings on Thursday

OptimizeRx (NASDAQ:OPRX) is expected to release its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect OptimizeRx to post earnings of $0.23 per share and revenue of $30.9150 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $7.79 on Thursday. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20. OptimizeRx has a 12-month low of $3.99 and a 12-month high of $22.25. The business’s 50 day moving average is $11.30 and its two-hundred day moving average is $15.18. The company has a market capitalization of $145.21 million, a P/E ratio of 19.10 and a beta of 1.18.

Wall Street Analyst Weigh In

OPRX has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Zacks Research cut OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Citizens Jmp raised their target price on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Stephens dropped their price target on OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a research report on Monday, November 17th. Finally, Wall Street Zen raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.50.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP acquired a new position in shares of OptimizeRx during the second quarter worth about $44,000. BNP Paribas Financial Markets increased its position in shares of OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the last quarter. Worth Venture Partners LLC acquired a new stake in shares of OptimizeRx in the 3rd quarter valued at $220,000. ExodusPoint Capital Management LP purchased a new stake in shares of OptimizeRx during the 4th quarter worth $150,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of OptimizeRx during the fourth quarter worth $158,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.